Business Context and Reporting Period
Company: Neuralstem, Inc. (Note: Metadata referenced "Palisade Bio," but the filing text identifies the registrant as Neuralstem, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Neuralstem is a clinical-stage biotechnology company focused on developing neural stem cell therapies for central nervous system diseases, primarily Amyotrophic Lateral Sclerosis (ALS). On September 21, 2009, the FDA approved the company's Investigational New Drug (IND) application to commence a Phase I clinical trial for ALS. The company has no commercial revenue and relies on external financing to fund operations.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2009 | Nine Months Ended Sept 30, 2009 | Balance Sheet (Sept 30, 2009) |
|---|---|---|---|
| Revenues | $0 | $0 | N/A |
| Net Loss | $(5,096,983) | $(7,380,751) | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.15) | $(0.22) | N/A |
| Operating Expenses | $2,522,582 | $8,158,789 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $2,420,715 |
| Total Assets | N/A | N/A | $3,051,872 |
| Total Liabilities | N/A | N/A | $7,975,596 |
| Stockholders' Deficit | N/A | N/A | $(4,923,724) |
| Warrant Liability (Long-term) | N/A | N/A | $5,622,339 |
Cash Flow (Nine Months Ended Sept 30, 2009):
- Net cash used in operating activities: $(3,613,084)
- Net cash used in investing activities: $(88,989)
- Net cash provided by financing activities: $1,219,509
- Net decrease in cash: $(2,482,564)
Material Changes vs. Prior Period
- Net Loss: The net loss for the three months ended September 30, 2009, increased to $5.1 million from $3.2 million in the same period in 2008. This increase was primarily driven by a $2.6 million non-cash loss from the change in fair value of warrant obligations. Conversely, the nine-month net loss decreased to $7.4 million from $8.4 million in 2008, due to a $0.76 million gain on warrant obligations offsetting higher operating expenses.
- Operating Expenses: Operating expenses decreased by $661,476 (21%) for the three months ended September 30, 2009, compared to 2008, due to reduced R&D spending and lower stock-based compensation. For the nine-month period, expenses decreased slightly by $289,255.
- Accounting Change: Effective January 1, 2009, the company reclassified approximately 8.5 million warrants from equity to liabilities due to new FASB guidance. This resulted in a long-term warrant liability of $5.6 million as of September 30, 2009, and contributed to a stockholders' deficit of $4.9 million.
- Liquidity: Cash and cash equivalents declined from $4.9 million at year-end 2008 to $2.4 million at September 30, 2009.
Guidance, Outlook, and Risks
Outlook and Guidance:
- The company anticipates no revenue in 2009 or the near future.
- Management estimates a monthly cash burn rate of approximately $425,000.
- As of September 30, 2009, cash reserves are sufficient to fund operations for approximately five months (into early 2010).
- The primary focus for the next 18 months is the Phase I clinical trial for ALS, estimated to cost $130,000 per patient for 12-18 patients.
Material Risks and Contingencies:
- Capital Requirements: The company must raise additional capital to continue operations and fund the ALS trial. Failure to secure financing could force a delay or elimination of development programs.
- Listing Compliance: Due to the reclassification of warrants, the company does not meet the stockholders' equity requirements for continued listing on the NYSE Amex. It is subject to a compliance plan to regain status by December 2010; failure could result in delisting to the OTC market.
- Legal Proceedings: Ongoing patent litigation with StemCells, Inc. regarding stem cell culture compositions. The outcome is uncertain and could be costly.
- Development Risk: No assurance that the ALS trial will succeed or that FDA approval will be granted for any product.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and monthly burn rate to confirm the estimated five-month runway remains accurate.
- Financing Plans: Review recent filings for updates on the shelf registration statement (Form S-3) and any new private placements to fund the ALS trial.
- Listing Status: Monitor communications from the NYSE Amex regarding the company's compliance plan to restore stockholders' equity.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the fair value of the $5.6 million warrant liability, which directly affects reported net income/loss.
- Clinical Trial Progress: Track the initiation and enrollment status of the Phase I ALS trial at Emory University.